慢性乙型肝炎患者队列中代谢功能障碍相关脂肪性肝病的危险因素
这项多中心研究纳入19个欧洲中心的1709例慢性乙型肝炎患者,MASLD患病率为42.3%,BMI、铁蛋白和2型糖尿病与MASLD独立相关,MASLD是进展期纤维化的独立预测因素,且MASLD患者随访48个月肝硬度无显著改善,无创标志物预测纤维化性能中等。
要点
- 慢性乙型肝炎患者中MASLD患病率为42.3%,进展期纤维化患病率为18%。
- BMI、铁蛋白和2型糖尿病与MASLD独立相关。
- MASLD患者进展期纤维化风险升高(OR 2.76),随访48个月肝硬度无显著改善。
核心结论
- 在这项大型欧洲队列中,慢性乙型肝炎患者中MASLD和纤维化患病率较高,MASLD加重肝纤维化,筛查策略仍不一致,铁蛋白水平、BMI升高和2型糖尿病可能提示MASLD的存在,生物标志物预测纤维化性能中等。
研究设计与样本
- 多中心研究,纳入来自19个欧洲中心的连续慢性乙型肝炎患者,共1709例,中位年龄53岁(四分位距42-64),男性占60.7%,BMI为25.6 kg/m2(四分位距14-63 kg/m2),白人占57.3%;另发放关于慢性乙型肝炎中MASLD筛查标准的调查问卷。
主要发现
- MASLD患病率(1510例连续患者)为42.3%。
- BMI(OR 1.27;95%CI 1.19-1.36)、铁蛋白(OR 1.00;95%CI 1.00-1.00)和2型糖尿病(OR 2.60;95%CI 1.12-6.02)与MASLD独立相关。
- 进展期纤维化患病率在全队列为18%(255/1420),在合并MASLD的慢性乙型肝炎患者中为25.4%(162/639),在无MASLD患者中为13.7%。
- 进展期纤维化的独立预测因素包括MASLD(OR 2.76;95%CI 1.50-5.05)、BMI(OR 1.08;95%CI 1.02-1.15)、丙氨酸转氨酶(OR 1.01;95%CI 1.00-1.03)、较低血小板(OR 0.99;95%CI 0.98-0.99)、胰岛素治疗(OR 13.88;95%CI 2.95-65.28)和长期抗病毒治疗(OR 4.86;95%CI 2.40-9.85)。
- 随访48个月期间,仅无MASLD患者显示肝硬度测量值随时间显著改善(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) commonly co-exist, with conflicting data in prevalence and disease severity. We aimed to investigate these discrepancies. METHODS: This multicenter study included consecutive patients with CHB from 19 European centers. A survey on standard of care for MASLD screening in CHB was circulated. RESULTS: A total of 1709 patients with CHB were included; median age, 53 years (interquartile range [IQR], 42-64); males, 60.7%; body mass index (BMI), 25.6 kg/m2 (IQR, 14-63 kg/m2); and 57.3% White. MASLD prevalence (1510 consecutive patients) was 42.3%. BMI (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.19-1.36), ferritin (OR, 1.00; 95% CI, 1.00-1.00) and type 2 diabetes (OR, 2.60; 95% CI, 1.12-6.02) were independently associated with MASLD. The prevalence of advanced fibrosis was 18% (255/1420) in the whole cohort, 25.4% (162/639) among patients with CHB with MASLD, and 13.7% in those without MASLD. Independent predictors of advanced fibrosis were MASLD (OR, 2.76; 95% CI, 1.50-5.05), BMI (OR, 1.08; 95% CI, 1.02-1.15), alanine transaminase (OR, 1.01; 95% CI, 1.00-1.03), lower platelets (OR, 0.99; 95% CI, 0.98-0.99), insulin treatment (OR, 13.88; 95% CI, 2.95-65.28), and long-term antivirals (OR, 4.86; 95% CI, 2.40-9.85). During follow-up (48 months), only patients without MASLD showed significant liver stiffness measurement improvement over time (P < .001). Among patients with MASLD, Fibrosis-4 and liver stiffness measurement performed moderately at predicting advanced fibrosis (area under the receiver operating characteristic curve = 0.71 vs 0.70; P = .38) against histology. As standard of care, 68.4% of centers screened all patients with CHB for MASLD; 52.6% followed the same treatment indication in those with CHB and MASLD vs CHB only. CONCLUSIONS: In this large European cohort, MASLD and fibrosis were highly prevalent among patients with CHB, whereas MASLD aggravated liver fibrosis. Though screening strategies remain inconsistent, ferritin levels, increased BMI, and type 2 diabetes may inform on the presence of MASLD. Biomarkers showed modest performance in predicting fibrosis.
引用
- Kalafateli M, Forlano R, Barnes E, et al. Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2025. PMID: 40609817. doi:10.1016/j.cgh.2025.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。